Triple hybrid amplicon vector systems to generate retroviral packaging lines

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6677155
SERIAL NO

09557910

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a triple hybrid vector amplicon system comprising genetic elements derived from Herpes Simplex Virus (HSV), Epstein-Barr Virus (EBV) or Adeno-Associated Virus (AAV), and a retrovirus. The vector was developed to stably transform cells, both in culture or in vivo, into retrovirus packaging cells in a single step. This step can be accomplished both by transfection using liposomes, electroporation, calcium phosphate, or any other methodology used to transfer naked or complexed DNA into cells or by infection when the vector is packaged as an amplicon vector in HSV virions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE GENERAL HOSPITAL CORPORATIONBOSTON, MA, US1241

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Breakefield, Xandra O Newton, MA 44 333
Saeki, Yoshinaga Toyama, JP 5 21
Sena-Esteves, Miguel Philadelphia, PA 2 3

Cited Art Landscape

Patent Info (Count) # Cites Year
 
THOMAS JEFFERSON UNIVERSITY (1)
5763242 Method for increasing transduction efficiency of recombinant retroviral vectors 5 1995
 
Human Gene Therapy Research Institute (1)
5830727 Herpes simplex virus amplicon mini-vector gene transfer system 26 1995
 
ATI MANUFACTURING LTD. (1)
5741486 Safe vectors for gene therapy 39 1995
 
UNIVERSITY OF ROCHESTER (1)
5601818 Cancer therapy utilizing malignant cells expressing HSV-TK 24 1994
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
5529774 In vivo transfer of the HSV-TK gene implanted retroviral producer cells 47 1991
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (1)
5756283 Method for improved production of recombinant adeno-associated viruses for gene therapy 58 1995
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
5830725 Rapid, stable high-titre production of recombing retrovirus 33 1995
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
5763217 Method of using, process of preparing and composition comprising recombinant herpesvirus vectors 20 1995
 
GENZYME CORPORATION (1)
5670488 Adenovirus vector for gene therapy 131 1993
 
THE GENERAL HOSPITAL CORPORATION (1)
5688773 Method of selectively destroying neoplastic cells 28 1994
 
OXFORD BIOMEDICA (UK) LIMITED (1)
5691177 Recombinant retroviruses expressing a protein that converts a pro-drug into a cytotoxic agent 44 1995
 
BAYLOR COLLEGE OF MEDICINE (1)
5631236 Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk 103 1993
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Institut National de Rechesche Scientifique (1)
8603784 Infectious clone of human parvovirus B19 and methods 0 2009
 
TOCAGEN INC. (1)
9320738 Formulations of 5-fluorocytosine and uses thereof 0 2009
 
INSTITUT NATIONAL DE RECHERCHE SCIENTIFIQUE (1)
7598071 Infectious clone of human parvovirus B19 and methods 0 2004
* Cited By Examiner